Ep 6- Dispelling Myths About Biosimilars

Biosimilars were first introduced into the US market about six years ago, but getting the all-important “patient buy-in” has been a slow process. Many patients are reluctant to switch to a biosimilar if they’re already happy taking a biologic. But another reason is the proliferation of myths and misinformation about biosimilars, which can be difficult to counteract.

In this episode, Zoe and Conner talk to a few medical professionals about the most common biosimilar falsehoods, and what can be done to stop their spread.

Among the highlights in this episode:

1:58 – The FDA begins cracking down on misinformation

2:47 – Myth #1: Patients confuse biosimilar drugs with generic drugs

3:06 – Doctors’ initial concerns about quality control

3:38 – Hesitancy about ‘transferability’

4:54 – Myth #2: Biosimilars won’t save money

5:50 – Myth #3: Biologics are natural monopolies

Contact Our Hosts:

Zoe Rothblatt, Patient Advocate and Community Outreach Manager at GHLF. [e-mail]

Conner Mertens, Patient Advocate and Community Outreach Manager at GHLF. [e-mail]

We’d love to hear what you think. Send your comments to [e-mail]

See omnystudio.com/listener for privacy information.